LFCR logo

LIFECORE BIOMEDICAL INC

LFCRNASDAQ
πŸ† #3571 by market capEarnings Feb 5US Equity
$6.58β–² $0.06 (+0.84%)
After hours Β· at close
πŸ””
Track LFCR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.8%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$247M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.5%
Slowing
πŸ“ŠGross Margin
29.7%
Moderate
πŸ’΅FCF Margin
-1.5%
Thin
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
72
Fair
No chart data available for LFCR.

Trading Snapshot

Day Range
$6.51 – $6.61
52-Week Range
$3.63 – $8.98
Volume
$2.61B
Avg Volume
$3.22B
Shares Outstanding
37.5M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$129M
Last Q Revenue
$34M
P/E Ratio
-5.9
P/S Ratio
2.0x
EPS (TTM)
$-0.99
Dividend Yield
0.00%
Dilution (1yr)
+8.9%

Why Investors Own LFCR

  • βœ“High-growth profile β€” revenue up +48.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 53% gross margin and 25% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LFCR logo

LIFECORE BIOMEDICAL INC

LFCR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$129Mβ–² +0.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
31.4%β–² +0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$1Mβ–Ό βˆ’92.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$14Mβ–Ό βˆ’24.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.4Mβ–² +8.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$119Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About LIFECORE BIOMEDICAL INC

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy4
Buy4
Hold3
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates